Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin
- PMID: 15007712
- DOI: 10.1007/s00467-003-1395-7
Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin
Abstract
Induction of experimental hemolytic uremic syndrome (HUS) by simply administering Shiga-like toxin (Stx) to rodents has not yet been successful. Attention has been paid to the role of lipopolysaccharide (LPS) in the pathogenesis of HUS. In this study, we showed successful induction of an experimental HUS in LPS responder mice by administering Stx together with LPS. Intraperitoneal administration of 200 ng of Stx 2 for 2 days, followed by 250 microg of LPS on the 2nd day of Stx administration, caused a significant decrease of thrombocytes and deterioration of renal function, with proteinuria and hematuria. Electron microscopy revealed alterations of glomerular endothelial cells. Administration of Stx alone or LPS alone caused neither hematological nor histopathological changes, as were observed with Stx and LPS co-administration. Interestingly, when LPS was administered before Stx, no hematological and histological changes were observed. The results showed that LPS was essential for the induction of HUS, but LPS pretreatment might protect against Stx toxicity. The order of LPS and Stx administration is important for the induction of experimental HUS.
Similar articles
-
von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.Pediatr Dev Pathol. 2002 Sep-Oct;5(5):472-9. doi: 10.1007/s10024-001-0204-1. Epub 2002 Aug 29. Pediatr Dev Pathol. 2002. PMID: 12196894
-
Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome.Am J Nephrol. 2001 Sep-Oct;21(5):420-5. doi: 10.1159/000046288. Am J Nephrol. 2001. PMID: 11684808
-
Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome.Pediatr Nephrol. 2001 Oct;16(10):823-39. doi: 10.1007/s004670100660. Pediatr Nephrol. 2001. PMID: 11605791 Review.
-
The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.Nephrol Dial Transplant. 2015 Jun;30(6):969-77. doi: 10.1093/ndt/gfv004. Epub 2015 Feb 17. Nephrol Dial Transplant. 2015. PMID: 25694534
-
Escherichia coli Shiga toxin.J Nat Toxins. 2000 Aug;9(3):299-313. J Nat Toxins. 2000. PMID: 10994531 Review.
Cited by
-
Molecular Lipopolysaccharide Di-Vaccine Protects from Shiga-Toxin Producing Epidemic Strains of Escherichia coli O157:H7 and O104:H4.Vaccines (Basel). 2022 Nov 1;10(11):1854. doi: 10.3390/vaccines10111854. Vaccines (Basel). 2022. PMID: 36366362 Free PMC article.
-
Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome.Am J Pathol. 2005 Jan;166(1):323-39. doi: 10.1016/S0002-9440(10)62256-0. Am J Pathol. 2005. PMID: 15632024 Free PMC article.
-
Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.Pediatr Nephrol. 2019 Mar;34(3):379-388. doi: 10.1007/s00467-017-3850-x. Epub 2017 Dec 6. Pediatr Nephrol. 2019. PMID: 29214442 Review.
-
Compensatory renal growth protects mice against Shiga toxin 2-induced toxicity.Pediatr Nephrol. 2006 Aug;21(8):1082-92. doi: 10.1007/s00467-006-0115-5. Epub 2006 May 16. Pediatr Nephrol. 2006. PMID: 16703367
-
Intestinal Stem Cell-on-Chip to Study Human Host-Microbiota Interaction.Front Immunol. 2021 Dec 6;12:798552. doi: 10.3389/fimmu.2021.798552. eCollection 2021. Front Immunol. 2021. PMID: 34938299 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources